Why the study?
The study was conducted to assess cardiovascular complication risks in patients with HFrEF based on sST2 and NT-proBNP levels at discharge and during long-term follow-up after ADHF treatment.
Do sST2 and NT-proBNP concentrations predict cardiovascular complications in patients with HFrEF after acute decompensation?
Do sST2 and NT-proBNP concentrations predict cardiovascular complications in patients with HFrEF after acute decompensation?
Simultaneous decrease of sST2 (≤23.4 ng/ml or by ≥34.3%) and NT-proBNP (≤1132 pg/ml or by ≥38.9%) within 6 months is associated with a lower risk of cardiovascular complications in HFrEF patients after acute decompensation.
Answers are grounded in this paper and cite their sources.
May aid post-decompensation risk stratification in HFrEF; leaves open whether serial monitoring improves outcomes.
Objective. To assess the risk of cardiovascular complications in patients with heart failure and reduced ejection fraction (HFrEF) depending on sST2 and NT-proBNP concentrations at discharge and in long-term follow-up after treatment of acute decompensated heart failure (ADHF). Material and methods. The study included 132 patients hospitalized for decompensated HFrEF due to coronary artery disease, dilated cardiomyopathy, and hypertension. Serum sST2 and NT-proBNP were analyzed at baseline, upon discharge, after 30, 90 and 180 days. The follow-up period was one year. We analyzed cardiovascular events including episodes of decompensation/hospitalization for HF and cardiovascular mortality. Results. The risk of cardiovascular events decreases within a year after discharge in case of serum sST2 and NT-proBNP at discharge <29.3 ng/mL (AUC 0.631±0.050, 95% CI: 0.534–0.728, p=0.010) and 2647 pg/mL (AUC 0.615±0.050, 95% CI: 0.518–0.713, p=0.024), respectively. Serum sST2≤23.4 ng/ml (AUC 0.746±0.051, 95% CI: 0.647–0.846, p<0.001) or decrease by ≥34.3% (20.8; 48.2), as well as NT-proBNP≤1132 pg/ml (AUC 0.757±0.049, 95% CI: 0.660–0.853, p<0.001) or decrease by ≥38.9% within 6 months was associated with lower risk of cardiovascular complications. This risk was high without simultaneous decrease of both biomarkers (OR=6.583; 95% CI 3.448–12.569, p<0.001). Conclusion. To reduce the risk of cardiovascular complications, it is necessary to achieve simultaneous decrease of sST2 ≤23.4 ng/ml or by ≥34.3% and NT-proBNP ≤1132 pg/ml or by ≥38.9%.
No takes yet. Share an insight, caveat, or question.
Narusov et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: